Literature DB >> 21333103

A cost-benefit analysis of scaling up tuberculosis control in India.

M Goodchild1, S Sahu, F Wares, P Dewan, R S Shukla, L S Chauhan, K Floyd.   

Abstract

OBJECTIVES: To measure the economic costs and benefits of scaling up tuberculosis (TB) control under the Revised National Tuberculosis Control Programme (RNTCP) in India.
DESIGN: Modelling based on country-level programme and epidemiological data from 1997 to 2006.
RESULTS: The scale-up of TB control in India has resulted in a total health benefit of 29.2 million disability-adjusted life years (DALYs), including 1.3 million deaths averted. In 2006, the burden of TB measured in terms of DALYs lost would have been 1.8 times higher in the absence of the programme. The total gain in economic well-being from TB control is estimated at US$88.1 billion over the 1997-2006 10-year period. Total public expenditure on TB control over this period amounted to US$768 million, with the RNTCP accounting for US$299 million and other health sector costs accounting for US$469 million. The cost of TB control averaged just US$26 per DALY gained over 1997-2006 and generated a return of US$115 per dollar spent.
CONCLUSIONS: The scale-up of TB control has been a very cost-effective strategy for improving the health status of India's population, while the return on investment has been exceptional from a societal perspective.

Entities:  

Mesh:

Year:  2011        PMID: 21333103

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  12 in total

Review 1.  Hemodialysis in Asia.

Authors:  Narayan Prasad; Vivekanand Jha
Journal:  Kidney Dis (Basel)       Date:  2015-11-18

Review 2.  Why India should become a global leader in high-quality, affordable TB diagnostics.

Authors:  Peter Small
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

3.  Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis.

Authors:  David W Dowdy; Karen R Steingart; Madhukar Pai
Journal:  PLoS Med       Date:  2011-08-09       Impact factor: 11.069

4.  Addressing poverty through disease control programmes: examples from Tuberculosis control in India.

Authors:  Vishnu Vardhan Kamineni; Nevin Wilson; Anand Das; Srinath Satyanarayana; Sarabjit Chadha; Kuldeep Singh Sachdeva; Lakbir Singh Chauhan
Journal:  Int J Equity Health       Date:  2012-03-26

Review 5.  Factors associated with patient and provider delays for tuberculosis diagnosis and treatment in Asia: a systematic review and meta-analysis.

Authors:  Jing Cai; Xianhua Wang; Aiguo Ma; Qiuzhen Wang; Xiuxia Han; Yong Li
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

6.  Counting the lives saved by DOTS in India: a model-based approach.

Authors:  Sandip Mandal; Vineet K Chadha; Ramanan Laxminarayan; Nimalan Arinaminpathy
Journal:  BMC Med       Date:  2017-03-03       Impact factor: 8.775

7.  Modelling the impact of effective private provider engagement on tuberculosis control in urban India.

Authors:  Nimalan Arinaminpathy; Sarang Deo; Simrita Singh; Sunil Khaparde; Raghuram Rao; Bhavin Vadera; Niraj Kulshrestha; Devesh Gupta; Kiran Rade; Sreenivas Achuthan Nair; Puneet Dewan
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

8.  Is a Mass Prevention and Control Program for Pandemic (H1N1) 2009 Good Value for Money? Evidence from the Chinese Experience.

Authors:  Biyan Wang; Jinliang Xie; Pengqian Fang
Journal:  Iran J Public Health       Date:  2012-11-01       Impact factor: 1.429

9.  Expenditure Pattern for TB Treatment among Patients Registered in an Urban Government DOTS Program in Chennai City, South India.

Authors:  Ramya Ananthakrishnan; M Muniyandi; Anita Jeyaraj; Gopal Palani; B W C Sathiyasekaran
Journal:  Tuberc Res Treat       Date:  2012-11-19

10.  Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.

Authors:  Sunil Khaparde; Neeraj Raizada; Sreenivas Achuthan Nair; Claudia Denkinger; Kuldeep Singh Sachdeva; Chinnambedu Nainarappan Paramasivan; Virender Singh Salhotra; Anna Vassall; Anja Van't Hoog
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.